NEW YORK (GenomeWeb News) – Goldman Sachs today downgraded Agilent Technologies and Genomic Health, but upgraded Waters.

The changes to the three firms' ratings are part of a "recalibrating" of the investment bank's Life Science Tools portfolio in light of tighter credit in China and an "underappreciated risk" of renewed austerity as the US Fiscal Year 2014 budget and debt ceiling "come back into focus," analyst Isaac Ro said in a research report.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.